ATRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Antares Pharma's Enterprise Value is $918.3 Mil. Antares Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $57.6 Mil. Therefore, Antares Pharma's EV-to-EBIT ratio for today is 15.95.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Antares Pharma's Enterprise Value is $918.3 Mil. Antares Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $61.5 Mil. Therefore, Antares Pharma's EV-to-EBITDA ratio for today is 14.93.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Antares Pharma's Enterprise Value is $918.3 Mil. Antares Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $183.5 Mil. Therefore, Antares Pharma's EV-to-Revenue ratio for today is 5.01.
The historical data trend for Antares Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 305.08 | 431.68 | 777.90 | 659.46 | 565.22 |
Antares Pharma Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Enterprise Value | Get a 7-Day Free Trial | 684.91 | 726.00 | 588.44 | 565.22 | 662.65 |
For the Medical Instruments & Supplies subindustry, Antares Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Antares Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Antares Pharma's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
Enterprise Value (A: Dec. 2021 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 607.15704 | + | 0 | + | 22.817 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.404 | + | 0 | - | 67.158 |
= | 565.2 |
Antares Pharma's Enterprise Value for the quarter that ended in Mar. 2022 is calculated as
Enterprise Value (Q: Mar. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 699.378 | + | 0 | + | 22.954 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.535 | + | 0 | - | 62.213 |
= | 662.7 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma (NAS:ATRS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Antares Pharma's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 918.341 | / | 57.573 | |
= | 15.95 |
Antares Pharma's current Enterprise Value is $918.3 Mil.
Antares Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.6 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Antares Pharma's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 918.341 | / | 61.511 | |
= | 14.93 |
Antares Pharma's current Enterprise Value is $918.3 Mil.
Antares Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $61.5 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Antares Pharma's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 918.341 | / | 183.456 | |
= | 5.01 |
Antares Pharma's current Enterprise Value is $918.3 Mil.
Antares Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $183.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Antares Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Carmen B Volkart | director | C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127 |
Peter C Richardson | officer: See Remarks | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Fred M Powell | officer: Executive Vice President & CFO | C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Thomas J Garrity | director | |
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Leonard S Jacob | director | C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022 |
Peter J Graham | officer: See Remarks | 315 E. 72ND ST., APT 5E, NEW YORK NY 10021 |
Peter Greenleaf | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Anton Gueth | director | |
Robert F Apple | director, officer: President & CEO | C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422 |
Marvin Samson | director | |
Jacques Gonella | director | C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341 |
James Patrick Tursi | officer: EVP, Chief Medical Officer | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Keith E Muckenhirn | officer: VP/Controller & Interim CFO | C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 07-29-2022
By PRNewswire PRNewswire • 06-01-2022
By PRNewswire PRNewswire • 05-09-2022
By PRNewswire PRNewswire • 04-13-2022
By PRNewswire PRNewswire • 05-06-2022
By Business Wire Business Wire • 04-26-2022
By PRNewswire PRNewswire • 05-29-2022
By Business Wire Business Wire • 05-02-2022
By PRNewswire PRNewswire • 05-12-2022
By PRNewswire PRNewswire • 04-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.